{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
BrightSpring Health Services, Inc.
BrightSpring Health Services Hits New 52-Week High of $69.83
BrightSpring Health Services, Inc. has achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. The company has demonstrated significant growth, with impressive financial metrics, including high operating cash flow and a notable increase in net profit, solidifying its market position.
BrightSpring Health Services Hits New 52-Week High of $67.83
BrightSpring Health Services, Inc. has achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. The company has demonstrated significant growth, robust financial metrics, and consistent profitability over the past six quarters, positioning itself favorably within the industry.
BrightSpring Health Services Hits New 52-Week High of $66.69
BrightSpring Health Services, Inc. has achieved a new 52-week high, reflecting strong growth in the Pharmaceuticals & Biotechnology sector. The company boasts impressive financial metrics, including a high operating cash flow and consistent profit growth over six quarters, alongside significant institutional investment support.
BrightSpring Health Services Hits New 52-Week High of $65.00
BrightSpring Health Services, Inc. has achieved a new 52-week high, reflecting its impressive performance in the Pharmaceuticals & Biotechnology sector with a significant increase over the past year. The company has strong financial metrics, including a notable market capitalization, robust operating cash flow, and positive net profit growth.
BrightSpring Health Services Hits New 52-Week High of $64.70
BrightSpring Health Services, Inc. has achieved a new 52-week high, reflecting its impressive performance in the Pharmaceuticals & Biotechnology sector with a significant increase over the past year. The company boasts strong financial metrics, including substantial net profit growth, high operating cash flow, and effective management of receivables.
BrightSpring Health Services Hits New 52-Week High of $63.49
BrightSpring Health Services, Inc. has achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector with significant one-year growth. The company boasts a market capitalization of USD 8,193 million, a P/E ratio of 41.00, and consistent positive financial results over the past six quarters.
BrightSpring Health Services Hits New 52-Week High of $62.30
BrightSpring Health Services, Inc. has achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector with a remarkable one-year growth. The company boasts a market capitalization of USD 8,193 million, a solid return on equity, and consistent net profit growth over the past six quarters.
BrightSpring Health Services Hits New 52-Week High of $62.09
BrightSpring Health Services, Inc. has achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. The company has demonstrated significant growth, impressive financial metrics, and consistent positive results over recent quarters, solidifying its market position and operational success.
BrightSpring Health Services Hits New 52-Week High of $60.89
BrightSpring Health Services, Inc. has achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. The company has experienced significant stock price growth over the past year, alongside impressive financial metrics, operational efficiency, and a notable increase in net profit.
BrightSpring Health Services Hits New 52-Week High of $60.48
BrightSpring Health Services, Inc. has achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. The company has significantly outperformed the S&P 500, boasting impressive financial metrics, including substantial net profit growth and a solid operating cash flow, reinforcing its favorable market position.
BrightSpring Health Services Hits New 52-Week High of $59.65
BrightSpring Health Services, Inc. has achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. With a market capitalization of USD 7,558 million, the company has reported significant growth, including a net profit increase and impressive financial metrics, showcasing its solid financial health.
BrightSpring Health Services Hits New 52-Week High of $44.87
BrightSpring Health Services, Inc. has achieved a new 52-week high, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company reported significant net profit growth and impressive operating cash flow, alongside a high interest coverage ratio and notable returns over the past year, highlighting its robust financial health.
BrightSpring Health Services, Inc. Announces Revision in Stock Evaluation Amid Mixed Market Indicators
BrightSpring Health Services, Inc. has recently experienced a stock price adjustment, currently at $40.13. The company has shown strong resilience over the past year, achieving a return of 108.47%, significantly outperforming the S&P 500. Various technical indicators present a mixed performance outlook for the stock.
BrightSpring Health Services: A Multibagger with 106.77% Return and 313.63% Net Profit Growth
BrightSpring Health Services, Inc. has recently undergone a revision in its score, reflecting its strong market position and impressive performance metrics. The stock has outperformed the S&P 500 significantly over the past year, showcasing robust financial health with substantial net profit growth and high institutional confidence.
Is BrightSpring Health Services, Inc. overvalued or undervalued?
As of October 17, 2025, BrightSpring Health Services, Inc. is considered undervalued with a P/E ratio of 37, an EV to EBITDA of 12.65, and a PEG ratio of 0.12, outperforming the S&P 500 with a year-to-date return of 74.57%.
BrightSpring Health Services, Inc. Experiences Revision in Stock Evaluation Amid Strong Performance Metrics
BrightSpring Health Services, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 37 and a low PEG ratio of 0.12, indicating growth potential. The company has outperformed the S&P 500 significantly over the past year, reflecting a strong market presence and competitive position within the Pharmaceuticals & Biotechnology sector.
Is BrightSpring Health Services, Inc. overvalued or undervalued?
As of October 17, 2025, BrightSpring Health Services, Inc. is considered undervalued with a P/E ratio of 37, a PEG ratio of 0.12 indicating strong growth potential, and a year-to-date return of 74.57%, outperforming the S&P 500's 13.30%.
Is BrightSpring Health Services, Inc. overvalued or undervalued?
As of October 17, 2025, BrightSpring Health Services, Inc. is considered undervalued with an attractive valuation grade, supported by a P/E ratio of 37, a PEG ratio of 0.12, and strong performance, significantly outperforming the S&P 500.
BrightSpring Health Services Hits New 52-Week High of $31.95
BrightSpring Health Services, Inc. reached a new 52-week high of USD 31.95 on October 15, 2025, reflecting a notable growth rate of 174.22% over the past year. The company, with a market capitalization of USD 4,514 million, showcases strong financial metrics, including a P/E ratio of 37.00.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
